BR112015020834A2 - novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1) - Google Patents

novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1)

Info

Publication number
BR112015020834A2
BR112015020834A2 BR112015020834A BR112015020834A BR112015020834A2 BR 112015020834 A2 BR112015020834 A2 BR 112015020834A2 BR 112015020834 A BR112015020834 A BR 112015020834A BR 112015020834 A BR112015020834 A BR 112015020834A BR 112015020834 A2 BR112015020834 A2 BR 112015020834A2
Authority
BR
Brazil
Prior art keywords
cyp1
hydroquinoline
derivatives
synthetase inhibitors
new
Prior art date
Application number
BR112015020834A
Other languages
English (en)
Inventor
V Mayweg Alexander
Hornsperger Benoit
Kuhn Bernd
P Maerki Hans
Aebi Johannes
Amrein Kurt
Tan Xuefei
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112015020834A2 publication Critical patent/BR112015020834A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1/1 resumo "novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1)" a invenção provê novos compostos apresentando a fórmula geral (1) em que r1, r2, r3, r4, r5, r6, r7, r9, r10 , r11 e a são como definidos no presente documento, composições incluindo os compostos e métodos de uso dos compostos. os compostos da fórmula (i) são úteis como inibidores da aldosterona sintetase (cyp11b2 ou cyp11b1) para o tratamento de vários transtornos.
BR112015020834A 2013-03-08 2014-03-05 novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1) BR112015020834A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013072348 2013-03-08
PCT/EP2014/054210 WO2014135561A1 (en) 2013-03-08 2014-03-05 New dihydroquinoline-2-one derivatives as aldosterone synthase (cyp1 1 b2 or cyp1 1 b1 ) inhibitors

Publications (1)

Publication Number Publication Date
BR112015020834A2 true BR112015020834A2 (pt) 2017-07-18

Family

ID=50193531

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015020834A BR112015020834A2 (pt) 2013-03-08 2014-03-05 novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1)

Country Status (9)

Country Link
US (1) US9458135B2 (pt)
EP (1) EP2964628B1 (pt)
JP (1) JP6574705B2 (pt)
BR (1) BR112015020834A2 (pt)
CA (1) CA2897417A1 (pt)
HK (1) HK1211937A1 (pt)
MX (1) MX2015010611A (pt)
RU (1) RU2015137972A (pt)
WO (1) WO2014135561A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150119207A (ko) * 2013-03-14 2015-10-23 에프. 호프만-라 로슈 아게 알도스테론 신타제 억제제로서 사용하기 위한 다이하이드로퀴놀린-2-온 유도체
WO2016066663A1 (en) * 2014-10-31 2016-05-06 F. Hoffmann-La Roche Ag Pyrazolyl-3,4-dihydroquinolin-2-one aldosterone synthase inhibitors
JP6670832B2 (ja) 2014-10-31 2020-03-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルドステロン合成酵素阻害剤としての新規ジヒドロキノリンピラゾリル化合物
CN106795138B (zh) * 2014-10-31 2020-04-14 豪夫迈·罗氏有限公司 新型二氢喹啉吡唑基化合物
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US20160287565A1 (en) 2015-04-06 2016-10-06 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT79699B (en) * 1983-12-22 1986-12-10 Pfizer Process for preparing quinolone inotropic agents
EA200900812A1 (ru) * 2006-12-18 2009-12-30 Новартис Аг Производные 4-имидазолил-1,2,3,4-тетрагидрохинолина и их применение в качестве ингибиторов альдостерон/11-бета-гидроксилазы
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
JP5883501B2 (ja) * 2011-04-26 2016-03-15 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルドステロンシンターゼインヒビター
ES2763332T3 (es) * 2011-09-15 2020-05-28 Hoffmann La Roche Nuevos derivados de dihidroquinolin-2-ona

Also Published As

Publication number Publication date
HK1211937A1 (en) 2016-06-03
WO2014135561A1 (en) 2014-09-12
JP6574705B2 (ja) 2019-09-11
MX2015010611A (es) 2015-12-16
EP2964628A1 (en) 2016-01-13
RU2015137972A (ru) 2017-04-13
EP2964628B1 (en) 2019-09-11
CA2897417A1 (en) 2014-09-12
US20160002207A1 (en) 2016-01-07
JP2016510055A (ja) 2016-04-04
US9458135B2 (en) 2016-10-04

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
BR112015022551A2 (pt) inibidores de amido pirrol
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
BR112018016433A2 (pt) inibidores de heteroarila de pad4
BR112015022861A2 (pt) inibidores de bromodomínio
BR112015022391A8 (pt) inibidores de domínio bromo tetracíclico
MX2015009270A (es) Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
BR112014027236A2 (pt) pirrolidinas substituídas como um fator inibidor de xia para o tratamento de doenças tromboembolíticas
BR112014013974A8 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
MX2016008110A (es) Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
EA201500362A1 (ru) Ингибиторы rho-киназы
BR112014017021A2 (pt) inibidores de irak e usos dos mesmos
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
BR112015020834A2 (pt) novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1)
NZ709985A (en) Nitroxyl donors with improved therapeutic index
BR112014010644A2 (pt) novos derivados de aril-quinolina
CL2015002346A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI